Heartware (HTWR) Commences MVAD System CE Mark Trial
Tweet Send to a Friend
Heartware (NASDAQ: HTWR) announced commencement of its MVAD System CE Mark international clinical trial. The first patients receiving HeartWare's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE